Clinical Trials

Showing 361 - 380 of 486 trials
Title Investigatorsort icon Disease(s)
A Phase I Study of Vemurafenib in Adolescents with Inoperable Stage IIIC/IV Melanoma with V600 BRAF Mutations
Newly Diagnosed & Relapsed/Refractory
[Protocol 11-198]
Pratilas, Christine
  • Melanoma
A Phase I/IIA Study of Dabrafenib in Children with Advanced BRAF Mutation-Positive Solid Tumors
[Protocol 13-016]
Pratilas, Christine
  • Melanoma
  • Pediatric Brain Tumors
  • Solid Tumors
A Study Analyzing Patients Treated for Wiskott-Aldrich Syndrome Since 1990
Newly Diagnosed & Relapsed/Refractory
[Protocol 14-066]
Prockop, Susan
  • Hematology
    • Hematologic Disorders
Expanded Access of Prochymal Infusion for the Treatment of Pediatric Patients with Acute Refractory GVHD
[Protocol 09-072]
Prockop, Susan
  • Blood and Marrow Transplantation
    • Transplantation
Development and Validation of a New Patient-Reported Outcome Instrument on the Impact of Altered Facial Appearance Following Oncologic Head and Neck Resection and Reconstruction
[Protocol 07-098]
Pusic, Andrea
  • Head & Neck Cancer
  • Survivorship
Microvascular Reconstruction for Advanced-Stage Head and Neck Cancer Patients: A Prospective Analysis of Quality of Life and Symptom Relief
[Protocol 07-150]
Pusic, Andrea
  • Head & Neck Cancer
  • Quality of Life
Quality of Life and Patient-Reported Outcomes After Breast Reconstruction Surgery
[Protocol 12-093]
Pusic, Andrea
  • Breast Cancer
  • Quality of Life
  • Survivorship
Mastectomy Reconstruction Outcomes Consortium (MROC) Study
[Protocol 11-175]
Pusic, Andrea
  • Breast Cancer
  • Survivorship
A Phase II Study of AUY922 in Patients with Myelofibrosis
Newly Diagnosed & Relapsed/Refractory
[Protocol 12-076]
Rampal, Raajit
  • Hematology
    • Hematologic Disorders
    • Hematologic Malignancies
  • Leukemia
    • Myeloproliferative Neoplasm
  • Rare Blood Disorders
A Phase II Study of MLN0128 in Men with Castration-Resistant Prostate Cancer
[Protocol 13-143]
Rathkopf, Dana
  • Prostate Cancer
    • Metastatic Disease after Hormone-Reducing Therapy
A Phase III Study of ARN-509 versus Placebo in Men with Non-Metastatic Castration-Resistant Prostate Cancer
[Protocol 13-243]
Rathkopf, Dana
  • Prostate Cancer
    • Rising PSA After Primary Therapy
A Phase IA/B Study of CC-115 in Castration-Resistant Prostate Cancer
[Protocol 12-080]
Rathkopf, Dana
  • Prostate Cancer
    • Metastatic Disease after Hormone-Reducing Therapy
A Study of Degarelix Before Prostatectomy in Patients with Intermediate- to High-Risk Prostate Cancer
[Protocol 11-182]
Rathkopf, Dana
  • Prostate Cancer
    • Localized Disease
A Phase Ib Study of ARN-509 plus Everolimus in Men with Progressive Metastatic Castration-Resistant Prostate Cancer After Abiraterone Therapy
[Protocol 13-025]
Rathkopf, Dana
  • Prostate Cancer
    • Metastatic Disease after Hormone-Reducing Therapy
A Phase II Study of Temozolomide Alone and with Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors
[Protocol 13-194]
Reidy-Lagunes, Diane
  • Upper Gastrointestinal
    • Neuroendocrine
    • Pancreatic Cancer
A Phase II Study of Bortezomib in Patients with KRAS-Mutant Non-Small Cell Lung Cancer
[Protocol 12-222]
Riely, Gregory
  • Lung Cancer, Non-Small Cell
A Phase I Study of EGF816 in Patients with Lung Cancer Containing the EGFR T790M Mutation
[Protocol 14-112]
Riely, Gregory
  • Lung Cancer, Non-Small Cell
A Phase I/II Study of Crizotinib and Ganetespib (STA-9090) in ALK-Positive Lung Cancers
[Protocol 12-015]
Riely, Gregory
  • Lung Cancer
  • Lung Cancer, Non-Small Cell
    • Lung Adenocarcinoma
A Phase I/II Study of the ALK Inhibitor CH5424802 in Patients with ALK-Rearranged Non-Small Cell Lung Cancer
[Protocol 12-113]
Riely, Gregory
  • Lung Cancer, Non-Small Cell
    • Lung Adenocarcinoma
A Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide
[Protocol 11-003]
Rimner, Andreas
  • Lung Cancer
  • Lung Cancer, Small Cell
    • Other